News articles about Cytosorbents Corporation (NASDAQ:CTSO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytosorbents Corporation earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.2758766714526 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- B. Riley Reaffirms Buy Rating for Cytosorbents Corporation (NASDAQ:CTSO) (americanbankingnews.com)
- GW Pharmaceuticals plc (GWPH) noted a price change of -2.13% and Cytosorbents Corporation (CTSO) closes with a … – Stocks Gallery (stocksgallery.com)
- Investors Are Turning Their Attention Towards Cytosorbents Corp (CTSO)’s Technicals – Sparta Review (spartareview.com)
- CytoSorbents’ (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- CytoSorbents reports 2Q loss (cnbc.com)
Shares of Cytosorbents Corporation (NASDAQ:CTSO) opened at 4.60 on Monday. Cytosorbents Corporation has a 52 week low of $3.30 and a 52 week high of $6.90. The firm’s market cap is $129.30 million. The company has a 50-day moving average price of $4.73 and a 200 day moving average price of $4.85.
Cytosorbents Corporation (NASDAQ:CTSO) last issued its earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02. The firm had revenue of $3.57 million for the quarter, compared to the consensus estimate of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. Analysts expect that Cytosorbents Corporation will post ($0.27) EPS for the current fiscal year.
Several brokerages recently commented on CTSO. Maxim Group set a $10.00 price target on Cytosorbents Corporation and gave the company a “buy” rating in a research note on Monday, July 17th. Aegis reaffirmed a “buy” rating and issued a $9.00 price target on shares of Cytosorbents Corporation in a research note on Tuesday, July 25th. B. Riley reaffirmed a “buy” rating and issued a $11.25 price target on shares of Cytosorbents Corporation in a research note on Wednesday, August 2nd. Finally, HC Wainwright set a $13.00 price target on Cytosorbents Corporation and gave the company a “buy” rating in a research note on Tuesday, August 8th. Six equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $12.71.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Cytosorbents Corporation (CTSO) Share Price” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/08/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-cytosorbents-corporation-ctso-share-price.html.
In other Cytosorbents Corporation news, insider Phillip P. Chan bought 6,300 shares of Cytosorbents Corporation stock in a transaction on Monday, June 5th. The shares were purchased at an average price of $4.00 per share, with a total value of $25,200.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders acquired 16,500 shares of company stock worth $66,280. Company insiders own 5.60% of the company’s stock.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.